IRS Logo
Print - Click this link to Print this page

Qualifying Therapeutic Discovery Project Grants for the State of North Carolina

The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.

The project descriptions below were extracted from the applicant certification forms as submitted.

North Carolina  $ 35,707,613.85
Applicant Name Project Name Grants Awarded for 2009 Grants Awarded for 2010
Advanced Liquid logic,Inc Development of a Digital Microfluidic Platform for Newborn Screening and Other Diagnostics $ 244,479.25  
Affinergy, Inc Localized delivery of therapeutics for sugical hernia repair meshes $ 103,735.44 $ 140,743.81
Affinergy, Inc Biologic Delivery Carrier for Spine Fusion $ 175,877.60 $ 68,601.64
Affinergy, Inc. Peptide Linkers and antimicrobial therapeutics for orthopedic surgery $ 244,479.24  
Affinergy, Inc. Enhanced Delivery of Protein Growth Factors for Trauma Fractures $ 244,479.24  
Affinergy, Inc. A Biological Cell-Binding Matrix for Treating Cardiovascular Disease $ 109,816.62 $ 69,122.45
Agarigen, Inc Mushrooms: A novel Platform for the Accelerated Production of Biopharmaceuticals $ 244,479.25  
Agile Sciences, Inc Development of Therapeutics for Treating Multidrug Resistant Bacterial Infections $ 25,353.50 $ 111,250.00
Aldagen, Inc Treatment of Critical Limb Ischemia Patients-No Revascularization Options - (CLI) ALD-301 $ 244,479.25  
Aldagen, Inc. Tereatment of Ischemic Heart Disease Patients - No Revascularization Options-ALD-201 $ 244,479.25  
Aldagen, Inc. Treatment of Post Acute Ischemic Stroke Patients - ALD-401   $ 244,479.25
Algynomics, Inc Novel Analgesic Discovery Project $ 65,881.50 $ 103,459.00
Algynomics, Inc. Diagnostic Genetic Tests for Chronic Pain Project $ 85,428.00 $ 150,104.00
AlphaVax Human Vaccines Inc Cytomegalovirus (CMV) Vaccine $ 244,479.25  
AlphaVax Human Vaccines, Inc. Scale-up Program $ 244,479.25  
Arbovax, Inc Host Range Mutants of Dengue Virus as Basis for Vaccine Development   $ 230,000.00
Argos Therapeutics, Inc AGS-004 $ 244,479.25  
Argos Therapeutics, Inc AGS-003 $ 244,479.25  
Argos Therapeutics, Inc AGS-009 (Intereron-alpha antibody)   $ 244,479.25
ASKLEPIOS BioPharmaceutical, Inc Gene Transfer of AAV Galanin for Epilepsy $ 149,171.00 $ 95,308.25
Asklepios BioPharmaceuticals, Inc. Gene Transfer of AAV Minidystrophin for Muscular Dystrophy $ 220,191.00 $ 24,288.25
Attagene, Inc. Predicting resistance of cancer to chemotherapy by profiling activities of transcription factor $ 244,479.25  
Avioq Inc. Avioq HIV-1 Microelisa System $ 244,479.25  
Avioq Inc. Avioq HTLV I/II Microelisa System for Use in Blood Screening and Diagnosis $ 67,913.46 $ 176,565.79
b3 bio, inc Targeted delivery of nucleic acids to silence cancer genes $ 244,479.24  
BioCytics Inc Molecular Profiling of Circulating Tumor Cells $ 133,946.50 $ 61,991.50
BioDelivery Sciences International, Inc Medical therapies utilizing BioErodible MucoAdhesive (BEMA) technology $ 244,479.25  
BioKier, Inc. Development of an Oral Therapeutic for the Treatment of Type 2 Diabetes $ 79,194.50 $ 165,284.75
Biolex Therapeutics, Inc. Locteron for the treatment of chronic hepatitis C virus $ 244,479.24  
BioLink Life Sciences, Inc Novel calcium nanoparticles for cancer detection & site-specific drug delivery $ 4,426.50 $ 21,112.50
BioLink Life Sciences, Inc Novel valproate salts with enhanced patient benefits $ 186,238.00 $ 44,162.00
BioLink Life Sciences, Inc Novel phosphate binders for treatment of hyperphosphatemia $ 13,424.50 $ 231,054.74
BioMarck Pharmaceuticals Ltd A Phase 2 Clinical Study of a COPD Therapeutic with a Novel Dual Mechanism of Action $ 244,479.24  
BioMedomics, Inc. Development of molecular diagnostic platforms & tests for personalized medicine diagnosis $ 136,875.50 $ 107,603.74
Brighthaven Ventures LLC Formulation and Pharmacokinetics Study of Remogliflozin   $ 236,350.00
CALVERT RESEARCH, LLC Calvert T1-1081 $ 195,750.00 $ 48,729.25
Cardioxyl Pharmaceuticals, Inc Oral HNO donors for treatment of Congestive Heart Failure (CHF) $ 244,479.24  
Cardioxyl Pharmaceuticals, Inc. CXL-1020:  A Novel Intravenous Treatment for Acute Decompensated heart Failure (ADHF) $ 244,479.24  
Catena Pharmaceuticals Inc Peclinical Development of VPC51299 a Novel LPA Receptor Antagonist $ 7,500.00 $ 10,000.00
CEM-102 Pharmaceuticals Inc CEM-102 (TAKSTA) Pre-clinical and clinical development $ 244,479.25  
Cempra Pharmaceuticals,  Inc CEM-101 (Solithromycin) $ 244,479.25  
CeNeRx BioPharma Inc TriRima $ 244,479.24  
CeNeRx BioPharma, Inc. Pivagabine $ 244,479.24  
Centice Corporation PASS Rx $ 244,479.24  
Centice Corporation Diagnostic reader for cardiac biomarkers $ 244,479.25  
Chelsea Therapetics, Inc Droxidopa $ 244,479.24  
Chelsea Therapeutics Inc Antifolates RA $ 244,479.24  
Chimerix Inc CMX001 dsDNA Antiviral Project $ 244,479.25  
Chimerix, Inc HCV Polymerase Inhibitors for the treatment of Hepatitis C $ 244,479.25  
CivaTech Oncology Inc. CivaTech Oncology Novel Brachytherapy Device $ 178,979.00  
Cognosci, Inc. Novel Remyelinating Therapy for Multiple Sclerosis $ 244,479.24  
Cognosci, Inc. Novel Targeted Therapy for Cancer $ 206,132.60 $ 38,346.64
Cognosci, Inc. Novel Therapy for Traumatic Brain Injury (TBI) and Neurotrauma $ 244,479.24  
CoLucid Pharmaceuticals, Inc. Lasmiditan (COL - 144) - Neurally Acting Anti-Migraine Agent $ 244,479.25  
Cytex Therapeutics,Inc. Bioartificial Hip Replacement $ 18,086.00 $ 226,393.25
DARA Pharmaceuticals, Inc. DB959 for Type 2 Diabetes & Dyslipidemia $ 244,479.24  
DARA Therapeutics, Inc KRN5500 for Neuropathic Pain in Patients with Cancer $ 244,479.24  
Diagnosoft, Inc Diagnosoft Heat Platform $ 149,187.00 $ 95,292.24
Endacea Inc Develop Endacea's lead compound, L-97-1, as an oral treatment for renal impairment with HF $ 10,150.00 $ 6,716.00
Endls Optics, Inc. Optical Assay for the Therapeutic Monitoring and Diagnosis of Cancer $ 51,610.50 $ 152,184.08
Exela Pharma Sciences, LLC Nitrofurantoin Sodium Injection $ 244,479.25  
FSC Laboratories, Inc Liquid Fosfomycin Tromethamine   $ 244,479.25
Furiex Pharmaceuticals Inc JNJ-IBS   $ 244,479.24
Furiex Pharmaceuticals, Inc JNJ-Q2   $ 244,479.24
Furiex Pharmaceuticals, Inc. PPD 10558   $ 244,479.24
Genova Diagnostics, Inc. Irritable Bowel Syndrome Evaluation & Treatment in Primary Care $ 4,319.00 $ 80,078.00
GlycoMark Inc Novel Early Detection Algorithm for Diabetes and Per-Diabetes $ 244,479.25  
G-Zero Therapeutics Inc G-Zero Pharmacoquiescence and Companion Diagnostic $ 46,989.00 $ 197,490.25
High Point Pharmaceuticals LLC HPP404 - H3 Antagonist - Novel New Therapeutic for Treatment of Obesity and Diabetes $ 244,479.25  
High Point Pharmaceuticals, LLC HPP593 - PPAR Delta Agonist - Novel New Therapeutic for Dyslipidemia and Diabetes $ 244,479.25  
High Point Pharmaceuticals, LLC HPP854 - BACE Inhibitor - Novel New Therapeutic for Treatment of Alzheimer's Disease $ 244,479.25  
High Point Pharmeceuticals HPP851-11B-HSD1 Antagonist - Novel New Therapeutic for Primary Open Angle Glaucoma $ 244,479.25  
Humacyte Inc New Therapy for kidney failure and vascular disease $ 244,479.25  
Hyperbranch Medical Technology Inc Therapeutic Hydrogels $ 244,479.24  
Icagen, Inc Novel Selective Sodium Channel Drugs to Treat chronic Pain $ 244,479.25  
Icagen, Inc. Novel KCNQ Agonists for the Treatment of Epilepsy and Pain $ 244,479.25  
Icagen, Inc. Novel TRPA1 Drugs to Treat Inflammatory Pain $ 244,479.25  
InnerPulse, Inc. Percutaneous Implantable Cardioverter-Defibrillator (PICD) $ 244,479.25  
Inspire Pharmaceuticals Inc Rho kinase inhibitors for opthalmic and pulmonary diseases $ 244,479.25  
Inspire Pharmaceuticals Inc Latrunculin Platform for Glaucoma $ 244,479.25  
Inspire Pharmaceuticals, Inc Blepharitis $ 244,479.25  
Inspire Pharmaceuticals, Inc Denufosol Tetrasodium $ 244,479.25  
Kainos Medicine USA, Inc. NNRTI KM-023   $ 135,303.61
KeraNetics LLC Product for Fluid Resuscitation $ 205,053.00 $ 39,426.25
KeraNetics LLC Product for Site-Directed Drug Delivery $ 244,479.25  
LIPOSCIENCE, INC. IMPACT OF LIPOPROTEIN PARTICLE ANALYSIS IN CARDIOVASCULAR RISK $ 39,875.00 $ 87,975.00
Liquidia Technologies Nanoparticle Vaccines Using PRINT Platform for Influenza and other Diseases $ 244,479.25  
Liquidia Technologies, Inc. PRINT Particle Engineering Platform and Inhaled Antiviral Therapeutics Development $ 244,479.25  
Mast Cell Pharmaceuticals Inc Effect of Ketotifen on Advfensiz Events Associates $ 19,377.50 $ 51,962.00
Medicago USA Demonstration of Scalable Manufacturing of Plant-Expressed Virus-Like Particles Vaccines   $ 244,479.25
Metabolon Inc Quantose Diagnostic $ 244,479.25  
Metabolon, Inc Platform Technology $ 244,479.25  
Morphormics, Inc. Auto-segmentation to Improve Radiation Therapy Cancer Treatment $ 244,479.24  
MYCOSYNTHETIX INC NEW CANCER MEDICINES FROM UNUSUAL FUNGI $ 25,244.50 $ 13,231.50
Mycosynthetix, Inc New Antibiotics for TB from Unusual Fungi $ 56,676.00 $ 13,231.50
Nanocor Therapeutics Inc Carfostin $ 244,479.25  
nContact Surgical Inc nContact's Focus: The Cure for Atrial Fibrillation $ 244,479.24  
NextRay, Inc NextRay $ 69,255.20 $ 175,224.04
Novan, Inc Nitric Oxide-Releasing Technology (nitricil™) to Fight Infection $ 244,479.25  
NovaTarg AMPK Activator for Cancer and Metabolic Diseases $ 7,061.52 $ 216,500.00
NovaTarg LKB1-AMPK Pathway Activator for Cancer $ 7,061.52 $ 237,417.72
NovaTarg (Kenneth William Batchelor) Liver Selective AMPK Activator for Type 2 Diabetes $ 7,061.52 $ 237,417.72
Ocean Therapeutics Inc Identification of medicinal drug candidates from marine organisms   $ 87,000.00
Ocean Therapeutics Inc Development of a new class of anti infectives from culturable marine organisms   $ 104,500.00
Ocean Therapeutics Inc Development of Brevenal, a new therapy for Cystic Fibrosis   $ 244,479.25
Onconix, Inc. Cervical Cancer Blood Test   $ 25,000.00
Oncoscope, Inc. Development of optical biopsy device for detecting pre-cancerous tissue in the espohagus $ 244,479.24  
OptoSonics,Inc Photoacoustic Imaging and Breast Cancer Therapy $ 244,479.24  
Oxygen Biotherapeutics Oxycyte drug for traumatic brain and spinal cord injury $ 244,479.25  
Parion Sciences, Inc Novel Treatment of Sjogren's Syndrome Xerostomia $ 244,479.24  
Parion Sciences, Inc. Novel Hydration Treatment for Dry Eye Disease $ 227,856.50 $ 16,622.74
Pathfinder Pharmaceuticals, Inc Restoration of Host Defense Leading to Safe, Effective Anticancer and Antiviral Drugs $ 38,426.00 $ 26,500.00
Piedmont Pharmaceuticals LLC Novel Head Lice Product $ 106,524.00 $ 103,892.50
Pique Therapeutics Inc Clinical Development of PT 107, Novel Therapy to Treat  Non-Small Cell Lung Cancer(NSCLC) $ 101,250.00 $ 82,364.50
Pisgah Laboratories Inc D/B/A Pisgah Labs, Inc Abuse Deterrent Hydrocodone Controlled Substance   $ 244,479.24
PLEXIGEN INC PLEXSTACK, A FOUR-DIMENSIONAL BIO-CHIP SYSTEM FOR PERSOALIZED MEDICINE $ 180,657.50 $ 63,821.75
POZEN Inc PA640 $ 244,479.25  
POZEN Inc. PN400 / VIMOVO $ 244,479.25  
POZEN Inc. PA32540 $ 244,479.25  
Precision BioSciences, Inc. BioProduction $ 190,983.76 $ 53,495.48
Salzburg Therapeutics, Inc FdUMP(N)Therapeutics for Cancer Treatment $ 5,904.94 $ 1,880.84
SCYNEXIS Inc SCY-641 cyclophilin inhibitor for treatment of keratoconjunctivitis $ 244,479.25  
SCYNEXIS Inc SCY-644 Single Drug Cyclophilin Inhibitor for HIV and HCV in Coinfected Population $ 244,479.25  
SCYNEXIS Inc Cyclophilin D Inhibitors as Protective Therapies in Muscle Injury and Disease $ 244,479.25  
Scynexis, Inc SCY-524 Oral Hepatitis C Therapy $ 244,479.25  
Seachaid Pharmaceuticals Inc Pre-clinical development of a novel glycopeptide for intravenous and oral delivery $ 114,330.50 $ 130,148.75
Seachaid Pharmaceuticals, Inc Oral delivery of the intravenous antibiotic cefepime $ 191,602.50 $ 52,876.75
Searchaid Pharmaceuticals, Inc Development of Oratonin, and Oral Derivative of Calcitonin $ 244,479.25  
Sicel Technologies Inc DVS Dosimeter Lung Project $ 33,407.65  
Sicel Technologies, Inc. DVS Electron Project $ 31,874.17 $ 5,000.00
Sicel Technologies, Inc. Ultra - HFT $ 40,760.50  
Sicel Technologies, Inc. F-18 - Sensor Technology $ 546.75 $ 75,000.00
Sirga Advanced Biopharma, Inc HIV drug development $ 87,179.00 $ 47,302.00
SureMilk, LLC Diagnosing and treating low caloric content in breast milk by means of a modified surface $ 34,877.00 $ 44,484.69
Synecor LLC Interventional Autonomics $ 26,886.00 $ 217,593.25
Synecor, LLC Inventional Oncology $ 112,395.50 $ 132,083.75
Synereca Pharmaceuticals, Inc. RecA inhibitors to restore and potentiate antibiotic effectiveness $ 896.50 $ 87,078.50
Targacept Inc Nueronal Nicotinic Receptor Modulators as treatments for Smoking Cessastion $ 244,479.25  
Targacept, Inc TC-5214 as a Treatment for Major Depressive Disorder (MDD) $ 239,077.50 $ 5,401.75
Targacept, Inc TC-6499 as a Treatment for Constipation Predominant Irritable Bowel Syndrome (IBS-C) $ 214,447.14 $ 30,032.11
Targacept, Inc TC-5619 as a Treatment for Various Cognitive Disorders $ 244,479.25  
Targacept, Inc. TC-6987 as a Treatment for Various Inflammator Disorders $ 244,479.25  
Targacept, Inc. Neuronal Nicotinic Receptor Modulators as Treatments for Parkinson's Disease $ 244,479.25  
TearScience, Inc Thermal Pulsation System ("LipiFlow") $ 244,479.24  
TearScience, Inc LipiView Ocular Surface Interferometer ("LipiView" ) $ 244,479.24  
Tensive Controls, Inc. Melanocortin Ligands in Disease Cachexia $ 13,940.60 $ 46,965.09
TheraLogics, Inc Treatmentof Inflammatory disorders & cancer with inhibitors of NF-kappaB $ 244,479.24  
TomoSoft Technologies, LLC Radiation dose reduction and image enhancement in medical diagnostic imaging $ 78,246.50 $ 166,232.75
Trana Discovery, Inc Staph aureus Antibiotic Drug Discovery Assay $ 100,462.50 $ 144,016.75
Trana Discovery, Inc Application of a Novel Anti-HIV Drug Discovery Assay $ 63,719.00 $ 66,900.00
TranS1, Inc Delivery of Therapeautic Nucleus Material Using a Minimally Invasive Implant System $ 244,479.25  
TransEnterix, Inc. The TransEnterix SPIDER Platform for Treatment of Obesity-Related Disorders and Cancer $ 244,479.24  
TransS1, Inc Modular Fusion Implant System for Fixation and Delivery of Therapeutic Agents $ 244,479.25  
TRANSTECH PHARMA INC. TTP4000-Rage Ligand Decoy - Novel New Therapeutic for Alzheimer's Disease $ 244,479.25  
TRANSTECH PHARMA, INC TTP054 - Glucagon-like Peptide 1 Agonist Novel New Therapeutic for Type 2 Diabetes $ 244,479.25  
TRANSTECH PHARMA, INC. TTP-GLUCOKINASE ACTIVATOR - NOVEL NEW THERAPEUTIC FOR TREATMENT of TYPE 2 DIABETES $ 244,479.25  
TRANSTECH PHARMA, INC. TTP607 Aurora Kinase Inhibitor Novel New Therapeutic for treatment of cancer $ 244,479.25  
TRANZYME, INC TZP-102 $ 244,479.25  
TRANZYME, INC. ULIMORELIN $ 244,479.25  
Vascular Pharamaceuticals, Inc Treatment of IGF-1 mediated atherosclerosis in diabetics via aVB3 receptor antagonism $ 161,905.50 $ 82,573.74
Viamet Pharmaceuticals Inc Novel Therapaeutic for the treatment of advanced prostate cancer (APO) $ 244,479.25  
Viamet Pharnaceuticals, Inc Novel Therapaeutic for the treatment of invasive fungal infection in humans $ 244,479.25  
Yukon Medical, LLC Advanced Drus Access and Delivery System $ 151,615.00 $ 92,864.25
Zinfandel Pharmaceuticals Inc Opportunity for the preventio of Alzheimers Disease $ 132,056.50 $ 112,422.75
Zor Pharmaceuticals, LLC Virulizin ® $ 244,479.25  

 

Page Last Reviewed or Updated: 05-Jun-2014